Are activation markers (CD25, CD38 and CD103) predictive of sensitivity to purine analogues in patients with T-cell prolymphocytic leukemia and other lymphoproliferative disorders?

Leukemia and Lymphoma

Volumn 43, Issue 12, 2002, Pages 2331-2334

  Delgado, Julio ^a   Buston, Jesus G ^a   Jimenez, Ma Carmen ^a   Quevedo, Evaristo ^a   Hernandez Navarro, Fernando ^a,b  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

CD103; CD25; CD38; Purine analogues; T cell prolymphocytic leukemia

Indexed keywords

ALEMTUZUMAB; CD103 ANTIGEN; CD2 ANTIGEN; CD3 ANTIGEN; CD38 ANTIGEN; CD4 ANTIGEN; CD5 ANTIGEN; CD7 ANTIGEN; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; INTERLEUKIN 2 RECEPTOR; METHOTREXATE; MONOCLONAL ANTIBODY; PENTOSTATIN; PREDNISONE; PURINE DERIVATIVE; VINCRISTINE SULFATE; ADENOSINE DIPHOSPHATE RIBOSYL CYCLASE; ALPHA E INTEGRINS; ALPHA INTEGRIN; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CD38 PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; MEMBRANE PROTEIN;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; CHRONIC DISEASE; CLINICAL FEATURE; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPHENOTYPING; LYMPHOPROLIFERATIVE DISEASE; MALE; PRIORITY JOURNAL; PROLYMPHOCYTIC LEUKEMIA; T CELL LEUKEMIA; DRUG EFFECT; DRUG RESISTANCE; LYMPHOCYTE ACTIVATION; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; REMISSION;

ADP-RIBOSYL CYCLASE; ANTIGENS, CD; ANTIGENS, CD38; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOPHENOTYPING; INTEGRIN ALPHA CHAINS; LEUKEMIA, PROLYMPHOCYTIC; LEUKEMIA, T-CELL; LYMPHOCYTE ACTIVATION; LYMPHOPROLIFERATIVE DISORDERS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PURINES; RECEPTORS, INTERLEUKIN-2; REMISSION INDUCTION;

EID: 0036890849     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/1042819021000040035     Document Type: Article

References (24)

1. Matutes, E., Brito-Babapulle, V., Swansbury, J., Ellis, J., Morilla, R., Dearden, C., Sempere, A. and Catovsky, D. (1991) "Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia", Blood 78, 3269-3274.
2. Garand, R., Goasguen, J., Brizard, A., Buisine, J., Charpentier, A., Claisse, J.F., Duchayne, E., Lagrange, M., Segonds, C., Troussard, X. and Flandrin, G. (1998) "Indolent course as a relatively frequent presentation in T-prolymphocytic leukaemia", British Journal of Haematology 103, 488-494.
3. Mercieca, J., Matutes, E., Dearden, C., MacLennan, K. and Catovsky, D. (1994) "The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype", Journal of Clinical Oncology 12, 2588-2593.
4. Dearden, C.E., Matutes, E., Cazin, B., Tjonnfjord, G.E., Parreira, A., Nomdedeu, B., Leoni, P., Clark, F.J., Radia, D., Rassam, S.M., Roques, T., Ketterer, N., Brito-Babapulle, V., Dyer, M.J. and Catovsky, D. (2001) "High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H", Blood 98, 1721-1726.
5. Erber, W.N. and Mason, D.Y. (1988) "Expression of the interleukin-2 receptor (Tac antigen/CD25) in hematologic neoplasms", American Journal of Clinical Pathology 89, 645-648.
6. Lenkei, R., Bratt, G., Holmberg, V., Muirhead, K. and Sandstrom, E. (1998) "Indicators of T-cell activation: correlation between quantitative CD38 expression and soluble CD8 levels in asymptomatic HIV+ individuals and healthy controls", Cytometry 33, 115-122.
7. Funaro, A., Morra, M., Calosso, L., Zini, M.G., Ausiello, C.M. and Malavasi, F. (1997) "Role of the human CD38 molecule in B cell activation and proliferation", Tissue Antigens 49, 7-15.
8. Hamblin, T.J., Orchard, J.A., Ibbotson, R.E., Davis, Z., Thomas, P.W., Stevenson, F.K. and Oscier, D.G. (2002) "CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease", Blood 99, 1023-1029.
9. Mulligan, S.P., Travade, P., Matutes, E., Dearden, C., Visser, L., Poppema, S. and Catovsky, D. (1990) "B-ly-7, a monoclonal antibody reactive with hairy cell leukemia, also defines an activation antigen on normal CD8+ T cells", Blood 76, 959-964.
10. Micklem, K.J., Dong, Y., Willis, A., Pulford, K.A., Visser, L., Durkop, H., Poppema, S., Stein, H. and Mason, D.Y. (1991) ssv "HML-1 antigen on mucosa-associated T cells, activated cells, and hairy leukemic cells is a new integrin containing the beta7 subunit", American Journal of Pathology 139, 1297-1301.
11. Dietz, S.B., Whitaker-Menezes, D. and Lessin, S.R. (1996) "The role of alphaE beta7 integrin (CD103) and E-cadherin in epidermotropism in cutaneous T-cell lymphoma", Journal of Cutaneous Pathology 23, 312-318.
12. Katoh, A., Ohshima, K., Kanda, M., Haraoka, S., Sugihara, M., Suzumiya, J., Kawasaki, C., Shimazaki, K., Ikeda, S. and Kikuchi, M. (2000) "Gastrointestinal T cell lymphoma: predominant cytotoxic: phenotypes, including alpha/beta, gamma/delta T cell and natural killer cells", Leukemia and Lymphoma 39, 97-111.
13. Pettitt, A.R., Zuzel, M. and Cawley, J.C. (1999) "Hairy-cell leukaemia: biology and management", British Journal of Haematology 106, 2-8.
14. Wollner, N., Burchenal, J.H., Lieberman, P.H., Exelby, P., D'Angio, G. and Murphy, M.L. (1976) "Non-Hodgkin's lymphoma in children. A comparative study of two modalities of therapy", Cancer 37, 123-134.
15. Johnson, S.A. and Thomas, W. (2000) "Therapeutic potential of purine analogue combinations in the treatment of lymphoid malignancies", Hematological Oncology 18, 141-153.
16. Saven, A. and Piro, L.D. (1994) "Newer purine analogues for the treatment of hairy-cell leukemia", New England Journal of Medicine 330, 691-697.
17. Kurzrock, R., Pilat, S. and Duvic, M. (1999) "Pentostatin therapy of T-cell lymphomas with cutaneous manifestations", Journal of Clinical Oncology 17, 3117-3121.
18. Robak, T. (2002) "The role of nucleoside analogues in the treatment of chronic lymphocytic leukemia-lessons learned from prospective randomized trials", Leukemia and Lymphoma 43, 537-548.
19. Mohammad, R.M., Katato, K., Almatchy, V.P., Wall, N., Liu, K.Z., Schultz, C.P., Mantsch, H.H., Varterasian, M. and al-Katib, A.M. (1998) "Sequential treatment of human chronic lymphocytic leukemia with bryostatin 1 followed by 2-chlorodeoxyadenosine: preclinical studies", Clinical Cancer Research 4, 445-453.
20. Ahmad, I., Al-Katib, A.M., Beck, F.W. and Mohammad, R.M. (2000) "Sequential treatment of a resistant chronic lymphocytic leukemia patient with bryostatin 1 followed by 2-chlorodeoxyadenosine: case report", Clinical Cancer Research 6, 1328-1332.
21. Hanson, C.A., Ward, P.C. and Schnitzer, B. (1989) "A multilobular variant of hairy cell leukemia with morphologic similarities to T-cell lymphoma", American Journal Surgical Pathology 13, 671-679.
22. Visser, L. and Poppema, S. (1990) "Induction of B-cell chronic lymphocytic leukaemia and hairy cell leukaemia like phenotypes by phorbol ester treatment of normal peripheral blood B-cells", British Journal of Haematology 75, 359-365.
23. Nair, C.N., Shinde, S., Kumar, A., Goyal, R., Nadkarni, K.S. and Advani, S.H. (1999) "Sezary cells with hairy projections", Leukemia Research 23, 195-197.
24. Diamandidou, E., Cohen, P.R. and Kurzrock, R. (1996) "Mycosis fungoides and Sezary syndrome", Blood 88, 2385-2409.